Access cutting-edge lung cancer treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access lung cancer specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related lung cancer treatment provided free
This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this lung cancer clinical trial in San Francisco, CA
If you're searching for lung cancer treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced lung cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.